Operational Costs Compared: SG&A Analysis of Dr. Reddy's Laboratories Limited and Verona Pharma plc

SG&A Expenses: A Decade of Change in Pharma Giants

__timestampDr. Reddy's Laboratories LimitedVerona Pharma plc
Wednesday, January 1, 2014387830000001802274
Thursday, January 1, 2015425850000002512761
Friday, January 1, 2016457020000002894488
Sunday, January 1, 2017463720000008096274
Monday, January 1, 2018469100000007985229
Tuesday, January 1, 2019488900000008994597
Wednesday, January 1, 20205012900000029772000
Friday, January 1, 20215455900000033907000
Saturday, January 1, 20226208100000026579000
Sunday, January 1, 202310593100000049868547
Monday, January 1, 202477201000000
Loading chart...

Unveiling the hidden dimensions of data

A Tale of Two Companies: SG&A Expenses in Focus

In the world of pharmaceuticals, operational efficiency is key to success. Dr. Reddy's Laboratories Limited and Verona Pharma plc offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. Over the past decade, Dr. Reddy's has seen a steady increase in SG&A costs, peaking in 2023 with a staggering 106% rise from 2014 levels. This reflects their expansive global operations and strategic investments. Meanwhile, Verona Pharma, a smaller player, has experienced a more volatile SG&A trajectory, with a notable spike in 2023, marking a 2,667% increase from 2014. This surge could indicate aggressive market entry strategies or increased R&D activities. However, data for 2024 is missing, leaving room for speculation on future trends. This comparison highlights the diverse strategies and challenges faced by pharmaceutical companies in managing operational costs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025